de Oliveira, Fabricio Ferreira, Bertolucci, Paulo Henrique Ferreira, Chen, Elizabeth Suchi, Smith, Marilia de Arruda Cardoso

To evaluate correlations of pharmacological treatment with cognitive and behavioral symptoms in patients with dementia due to Alzheimer’s disease with low schooling, subjects were assessed for demographic features, neuropsychiatric symptoms, cognitive decline, functionality, caregiver burden, APOE haplotypes and pharmacological treatment. Among 217 patients, use of cholinesterase inhibitors with or without Memantine was associated with less […]

Cumbo, Eduardo, Ligori, Leonarda Domenica

Background: Behavioral and psychological symptoms of dementia (BPSD) occur in up to 80% of Alzheimer’s disease (AD) patients and represent one of the most common reasons for early institutionalization and increase in management costs.; Objectives: This study evaluated the effects of four drugs (memantine, donepezil, rivastigmine, galantamine) in BPSD in AD patients.; Methods: This was […]

Choi, Seong Hye, Park, Kyung Won, Na, Duk L., Han, Hyun Jeong, Kim, Eun-Joo, Shim, Yong S., Lee, Jae-Hong, The EXPECT Study Group,

Objective: To compare the tolerability and efficacy of combination therapy of memantine plus rivastigmine patch with rivastigmine patch monotherapy in patients with mild to moderate Alzheimer’s disease (AD).; Research Design and Methods: In this multicenter, randomized, open-label study, patients entered an 8-week run-in period (a 5 cm 2 rivastigmine patch for 4 weeks, then a […]

Carcaillon, L., Berrut, G., Sellal, F., Dartigues, J. F., Gillette, S., Pere, J. J., Bourdeix, I.

Background: Patients with Alzheimer’s disease (AD) who deteriorate rapidly are likely to have a poorer prognosis. There is a clear need for a clinical assessment tool to detect such a decline in newly diagnosed patients.; Objective: To identify the predictive factors of rapid cognitive decline (RCD) in a cohort of patients with mild to moderate […]

Babai, Samy, Auriche, Pascal, Le-Louët, Hervé

Background: Since donepezil and memantine are currently used for treating Alzheimer’s disease, it is interesting to analyse, reassess and compare their safety profile in order to promote a better use.; Methods: All spontaneous reports of suspected serious adverse drug reactions with donepezil alone and with memantine alone recorded in the French Pharmacovigilance Database during 6 […]

Aarsland, Dag, Ballard, Clive, Walker, Zuzana, Bostrom, Fredrik, Alves, Guido, Kossakowski, Katja, Leroi, Iracema, Pozo-Rodriguez, Francisco, Minthon, Lennart, Londos, Elisabet

Background: Dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD) are common forms of dementia that substantially affect quality of life. Currently, the only treatment licensed for PDD is rivastigmine, and there are no licensed treatments for DLB. We aimed to test the safety and efficacy of the N-methyl D-aspartate (NMDA) receptor antagonist memantine […]